Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR)

Bart Reymen; Angela Van Baardwijk; Rinus Wanders; Jacques Borger; Anne Marie C. Dingemans; Gerben Bootsma; Cordula Pitz; Ragnar Lunde; Wiel Geraedts; Philippe Lambin; Dirk De Ruysscher

doi:10.1016/j.radonc.2013.12.005

Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR)

Bart Reymen^*, Angela Van Baardwijk, Rinus Wanders, Jacques Borger, Anne Marie C. Dingemans, Gerben Bootsma, Cordula Pitz, Ragnar Lunde, Wiel Geraedts, Philippe Lambin, Dirk De Ruysscher

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

30 Citations (Scopus)

Abstract

Background:

Non-small cell lung cancer (NSCLC) stage T4N0-1 or single nodal station IIIA-N2 are two stage III sub-groups for which the outcome of non-surgical therapy is not well known. We investigated the results of individualised isotoxic accelerated radiotherapy (INDAR) and chemotherapy in this setting.

Methods:

Analysis of NSCLC patients included in 2 prospective trials (NCT00573040 and NCT00572325) stage T4N0-1 or IIIA-N2 with 1 pathologic nodal station, treated with chemo-radiotherapy (CRT) using INDAR with concurrent or sequential platinum-based chemotherapy. Overall survival (OS) was updated and calculated from date of diagnosis (Kaplan-Meier). Toxicity was scored following CTCAEv3.0. To allow comparison with other articles the subgroups were also analysed separately for toxicity, progression free and overall survival.

Results:

83 patients (42 T4N0-1 and 41 IIIA-N2) were identified: the median radiotherapy dose was 65 Gy. Thirty-seven percent of patients received sequential CRT and 63% received concurrent CRT. At a median follow-up of 48 months the median OS for T4N0-1 patients was 34 months with 55% 2-year survival and 25% 5-year survival. For stage IIIA-N2 at a median follow-up of 50 months the median OS was 26 months with 2- and 5-year survival rates of 53% and 24%, respectively.

Conclusion:

Chemo-radiation using INDAR yields promising survival results in patients with single-station stage IIIA-N2 or T4N0-1 NSCLC.

Original language	English
Pages (from-to)	482-487
Number of pages	6
Journal	Radiotherapy and Oncology
Volume	110
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2013.12.005
Publication status	Published - Mar 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.radonc.2013.12.005

Cite this

Reymen, B., Van Baardwijk, A., Wanders, R., Borger, J., Dingemans, A. M. C., Bootsma, G., Pitz, C., Lunde, R., Geraedts, W., Lambin, P., & De Ruysscher, D. (2014). Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiotherapy and Oncology, 110(3), 482-487. https://doi.org/10.1016/j.radonc.2013.12.005

@article{9ca824c54e9e4a34b7542f70e8cbb01c,

title = "Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR)",

abstract = "Background:Non-small cell lung cancer (NSCLC) stage T4N0-1 or single nodal station IIIA-N2 are two stage III sub-groups for which the outcome of non-surgical therapy is not well known. We investigated the results of individualised isotoxic accelerated radiotherapy (INDAR) and chemotherapy in this setting. Methods:Analysis of NSCLC patients included in 2 prospective trials (NCT00573040 and NCT00572325) stage T4N0-1 or IIIA-N2 with 1 pathologic nodal station, treated with chemo-radiotherapy (CRT) using INDAR with concurrent or sequential platinum-based chemotherapy. Overall survival (OS) was updated and calculated from date of diagnosis (Kaplan-Meier). Toxicity was scored following CTCAEv3.0. To allow comparison with other articles the subgroups were also analysed separately for toxicity, progression free and overall survival. Results:83 patients (42 T4N0-1 and 41 IIIA-N2) were identified: the median radiotherapy dose was 65 Gy. Thirty-seven percent of patients received sequential CRT and 63% received concurrent CRT. At a median follow-up of 48 months the median OS for T4N0-1 patients was 34 months with 55% 2-year survival and 25% 5-year survival. For stage IIIA-N2 at a median follow-up of 50 months the median OS was 26 months with 2- and 5-year survival rates of 53% and 24%, respectively. Conclusion:Chemo-radiation using INDAR yields promising survival results in patients with single-station stage IIIA-N2 or T4N0-1 NSCLC.",

author = "Bart Reymen and {Van Baardwijk}, Angela and Rinus Wanders and Jacques Borger and Dingemans, {Anne Marie C.} and Gerben Bootsma and Cordula Pitz and Ragnar Lunde and Wiel Geraedts and Philippe Lambin and {De Ruysscher}, Dirk",

year = "2014",

month = mar,

doi = "10.1016/j.radonc.2013.12.005",

language = "English",

volume = "110",

pages = "482--487",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

Reymen, B, Van Baardwijk, A, Wanders, R, Borger, J, Dingemans, AMC, Bootsma, G, Pitz, C, Lunde, R, Geraedts, W, Lambin, P & De Ruysscher, D 2014, 'Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR)', Radiotherapy and Oncology, vol. 110, no. 3, pp. 482-487. https://doi.org/10.1016/j.radonc.2013.12.005

Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). / Reymen, Bart; Van Baardwijk, Angela; Wanders, Rinus et al.
In: Radiotherapy and Oncology, Vol. 110, No. 3, 03.2014, p. 482-487.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR)

AU - Reymen, Bart

AU - Van Baardwijk, Angela

AU - Wanders, Rinus

AU - Borger, Jacques

AU - Dingemans, Anne Marie C.

AU - Bootsma, Gerben

AU - Pitz, Cordula

AU - Lunde, Ragnar

AU - Geraedts, Wiel

AU - Lambin, Philippe

AU - De Ruysscher, Dirk

PY - 2014/3

Y1 - 2014/3

N2 - Background:Non-small cell lung cancer (NSCLC) stage T4N0-1 or single nodal station IIIA-N2 are two stage III sub-groups for which the outcome of non-surgical therapy is not well known. We investigated the results of individualised isotoxic accelerated radiotherapy (INDAR) and chemotherapy in this setting. Methods:Analysis of NSCLC patients included in 2 prospective trials (NCT00573040 and NCT00572325) stage T4N0-1 or IIIA-N2 with 1 pathologic nodal station, treated with chemo-radiotherapy (CRT) using INDAR with concurrent or sequential platinum-based chemotherapy. Overall survival (OS) was updated and calculated from date of diagnosis (Kaplan-Meier). Toxicity was scored following CTCAEv3.0. To allow comparison with other articles the subgroups were also analysed separately for toxicity, progression free and overall survival. Results:83 patients (42 T4N0-1 and 41 IIIA-N2) were identified: the median radiotherapy dose was 65 Gy. Thirty-seven percent of patients received sequential CRT and 63% received concurrent CRT. At a median follow-up of 48 months the median OS for T4N0-1 patients was 34 months with 55% 2-year survival and 25% 5-year survival. For stage IIIA-N2 at a median follow-up of 50 months the median OS was 26 months with 2- and 5-year survival rates of 53% and 24%, respectively. Conclusion:Chemo-radiation using INDAR yields promising survival results in patients with single-station stage IIIA-N2 or T4N0-1 NSCLC.

AB - Background:Non-small cell lung cancer (NSCLC) stage T4N0-1 or single nodal station IIIA-N2 are two stage III sub-groups for which the outcome of non-surgical therapy is not well known. We investigated the results of individualised isotoxic accelerated radiotherapy (INDAR) and chemotherapy in this setting. Methods:Analysis of NSCLC patients included in 2 prospective trials (NCT00573040 and NCT00572325) stage T4N0-1 or IIIA-N2 with 1 pathologic nodal station, treated with chemo-radiotherapy (CRT) using INDAR with concurrent or sequential platinum-based chemotherapy. Overall survival (OS) was updated and calculated from date of diagnosis (Kaplan-Meier). Toxicity was scored following CTCAEv3.0. To allow comparison with other articles the subgroups were also analysed separately for toxicity, progression free and overall survival. Results:83 patients (42 T4N0-1 and 41 IIIA-N2) were identified: the median radiotherapy dose was 65 Gy. Thirty-seven percent of patients received sequential CRT and 63% received concurrent CRT. At a median follow-up of 48 months the median OS for T4N0-1 patients was 34 months with 55% 2-year survival and 25% 5-year survival. For stage IIIA-N2 at a median follow-up of 50 months the median OS was 26 months with 2- and 5-year survival rates of 53% and 24%, respectively. Conclusion:Chemo-radiation using INDAR yields promising survival results in patients with single-station stage IIIA-N2 or T4N0-1 NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84899581762&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2013.12.005

DO - 10.1016/j.radonc.2013.12.005

M3 - Article

C2 - 24444527

AN - SCOPUS:84899581762

SN - 0167-8140

VL - 110

SP - 482

EP - 487

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 3

ER -

Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this